PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (NASDAQ: PTCT) has announced the approval of 1,200 restricted stock units (RSUs) to two new employees as part of their employment compensation. The RSUs were granted on January 3, 2025, under the Nasdaq inducement grant exception and approved by PTC's Compensation Committee.
Each RSU represents the right to receive one share of common stock upon vesting. The vesting schedule spans four years, with 25% of the original shares vesting annually on each employee's hire date anniversary, contingent upon continued employment with the company.
PTC Therapeutics (NASDAQ: PTCT) ha annunciato l'approvazione di 1.200 unità azionarie ristrette (RSU) a due nuovi dipendenti come parte della loro compensazione lavorativa. Le RSU sono state concesse il 3 gennaio 2025, ai sensi dell'eccezione per concessioni di indennità Nasdaq e approvate dal Comitato per la Compensazione di PTC.
Ogni RSU rappresenta il diritto di ricevere un'azione ordinarie al momento della maturazione. Il programma di maturazione si estende su quattro anni, con il 25 % delle azioni originali che matura annualmente nell'anniversario della data di assunzione di ciascun dipendente, a condizione del mantenimento dell'impiego con l'azienda.
PTC Therapeutics (NASDAQ: PTCT) ha anunciado la aprobación de 1,200 unidades de acciones restringidas (RSU) para dos nuevos empleados como parte de su compensación laboral. Las RSU se otorgaron el 3 de enero de 2025, bajo la excepción de concesión de incentivos de Nasdaq y aprobadas por el Comité de Compensación de PTC.
Cada RSU representa el derecho a recibir una acción ordinaria una vez que madure. El calendario de maduración abarca cuatro años, con el 25 % de las acciones originales madurando anualmente en el aniversario de la fecha de contratación de cada empleado, condicionado a la continuidad de empleo con la empresa.
PTC Therapeutics (NASDAQ: PTCT)는 두 명의 신입 사원에게 고용 보상의 일환으로 1,200개의 제한 주식 단위(RSU)의 승인을 발표했습니다. 이 RSU는 2025년 1월 3일에 부여되었으며, 나스닥 유도 보상 예외에 따라 PTC의 보상 위원회에 의해 승인되었습니다.
각 RSU는 권리가 생기면 보통주 한 주를 받을 수 있는 권리를 나타냅니다. 보유 일정은 4년에 걸쳐 있으며, 원래 주식의 25%가 각 직원의 고용 기념일마다 매년 발생하며, 회사에서 계속 근무하는 조건입니다.
PTC Therapeutics (NASDAQ: PTCT) a annoncé l'approbation de 1 200 unités d'actions restreintes (RSU) pour deux nouveaux employés dans le cadre de leur compensation salariale. Les RSU ont été accordées le 3 janvier 2025, selon l'exception de concession d'incitation de Nasdaq et approuvées par le Comité de rémunération de PTC.
Chaque RSU représente le droit de recevoir une action ordinaire au moment de l'acquisition. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % des actions originales acquérant chaque année à l'anniversaire de l'embauche de chaque employé, sous réserve du maintien de l'emploi au sein de l'entreprise.
PTC Therapeutics (NASDAQ: PTCT) hat die Genehmigung von 1.200 beschränkten Aktieneinheiten (RSUs) für zwei neue Mitarbeiter im Rahmen ihrer Beschäftigungsvergütung bekannt gegeben. Die RSUs wurden am 3. Januar 2025 im Rahmen der Nasdaq-Anreizgewährungsausnahme vergeben und vom Vergütungsausschuss von PTC genehmigt.
Jede RSU stellt das Recht dar, eine Stammaktie nach der Vestingzeit zu erhalten. Der Vesting-Zeitraum erstreckt sich über vier Jahre, wobei 25 % der ursprünglichen Aktien jährlich am Jahrestag des Einstellungsdatums jedes Mitarbeiters fällig werden, vorausgesetzt, dass das Arbeitsverhältnis mit dem Unternehmen fortgesetzt wird.
- Implementation of employee retention strategy through equity-based compensation
- Potential future dilution of existing shareholders due to new RSU issuance
The inducement grants were approved by PTC's Compensation Committee on Jan. 3, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs each will vest over four years with
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn and X.
For more information please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302349732.html
SOURCE PTC Therapeutics, Inc.
FAQ
How many RSUs did PTC Therapeutics (PTCT) grant on January 3, 2025?
What is the vesting schedule for PTCT's January 2025 RSU grants?
How many new employees received RSUs from PTCT in January 2025?
Under which Nasdaq rule were PTCT's January 2025 RSUs granted?
